scholarly journals Natural Killer Cell and Large Granular Lymphocyte Deficiency in the Gut of Children with Inflammatory Bowel Disease

1990 ◽  
Vol 4 (7) ◽  
pp. 303-308 ◽  
Author(s):  
F Hadziselimovic ◽  
LR Emmons ◽  
U Schaub

The occurrence of natural killer cells and large granular lymphocytes (LGL) within the epithelium of colonic mucosa in children with inflammatory bowel disease (IBD) was compared to normal controls. Their numbers and localization within the epithelium from various regions of the colon were analyzed with immunohistochemical techniques using fluorescent, light and electron microscopy. The average number of natural killer cells and LGL in normal controls was 3.0±1.l per mn2. In contrast, there were no natural killer cells in the gut epithelium of children with IBD, irrespective of disease activity, whether the biopsy specimens were obtained from involved or uninvolved inflammatory regions of the gut, or the treatment status of the patients. However, the number of natural killer cells was normal in patients in remission with left-sided colitis. The lack of natural killer cells and LGL in the gut epithelium in children with IBD may be indicative of a possible genetic predisposition. The authors also present a new therapeutic strategy consisting of low dose interferon-alpha-2a that is efficacious in ameliorating ulcerative col iris and Crohn's disease and concomitantly increasing the number of natural killer cells and LGL in the gut.

2021 ◽  
Vol 160 (6) ◽  
pp. S-515-S-516
Author(s):  
Francisco Trelles ◽  
Anabelle Cloutier ◽  
Andrea Herrera-Gayol ◽  
Roberto Rodriguez-Suarez ◽  
Katia Betito

2007 ◽  
Vol 7 (3) ◽  
pp. 281-286 ◽  
Author(s):  
Y. VAN DE WAL ◽  
A. VAN DER SLUYS VEER ◽  
H. W. VERSPAGET ◽  
T. P. J. MULDER ◽  
G. GRIFFIOEN ◽  
...  

PEDIATRICS ◽  
2010 ◽  
Vol 126 (4) ◽  
pp. e977-e981 ◽  
Author(s):  
M. Deneau ◽  
J. Wallentine ◽  
S. Guthery ◽  
M. O'Gorman ◽  
J. Bohnsack ◽  
...  

2020 ◽  
Vol 21 (12) ◽  
pp. 1176-1185 ◽  
Author(s):  
Tuğcan Korak ◽  
Emel Ergül ◽  
Ali Sazci

Background: In the last decade, there have been accumulating data that the use of medicinal plants could bring additional benefits to the supportive treatment of various diseases. Nigella sativa (N. sativa, family Ranunculaceae) is one of these plants that has attracted considerable interest. The extracts and seeds of N. sativa and its active component thymoquinone have been studied extensively and the results suggest that N. sativa might carry some therapeutic potential for many diseases, including cancer. Methods: The selection criteria for references were applied through Pubmed with “N. sativa and cancer”, “N. sativa and breast cancer”, “N. sativa and metastasis”, “N. sativa and cytotoxicity of natural killer cells”. The pathway analysis was performed using the PANTHER tool by using five randomly selected N. sativa affected genes (Cyclin D1, P53, p21 protein (Cdc42/Rac) activated kinase 1 (PAK1), B-cell lymphoma 2 (Bcl-2) and vascular endothelial growth factor (VEGF)) in order to elucidate further potentially affected signaling pathways. Results: The aim of this review was to summarize studies regarding the effects of N. sativa in cancer generally, with a focus on breast cancer, its anti-metastatic effects, and how N. sativa modulates the cytotoxicity of Natural Killer cells that play a crucial role in tumor surveillance. Conclusion: In summary, the data suggest that N. sativa might be used for its anti-cancer and antimetastatic properties and as an immune system activator against cancer.


Sign in / Sign up

Export Citation Format

Share Document